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Re-engineering Drug Discovery and Development
Abstract
The rate of new drug approvals in the US has remained essentially constant since 1950, while the costs of
drug development have soared. Many commentators question the sustainability of the current model of
drug development, in which large pharmaceutical companies incur markedly escalating costs to deliver
the same number of products to market. This Issue Brief summarizes the problem, describes ongoing
governmental efforts to influence the process, and suggests changes in regulatory science and
translational medicine that may promote more successful development of safe and effective
therapeutics.
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Re-engineering Drug Discovery
and Development
Editor’s note: The rate of new drug approvals in the US has remained essentially
constant since 1950, while the costs of drug development have soared. Many
commentators question the sustainability of the current model of drug development,
in which large pharmaceutical companies incur markedly escalating costs to deliver
the same number of products to market. This Issue Brief summarizes the problem,
describes ongoing governmental efforts to influence the process, and suggests changes
in regulatory science and translational medicine that may promote more successful
development of safe and effective therapeutics.

Despite enormous investments in drug discovery and development, the number of new
molecular entities (NMEs) annually approved by the Food and Drug Administration
(FDA) has hovered around 20-25 for the past 60 years. The rate-limiting step occurs at
drug development, not drug target discovery. New molecular and genomic technologies
have produced far more potential drug targets than can be pursued through the
current development process. Targets, and the chemistry needed to probe them, can
be selected more rationally than ever—yet more and more candidate drugs are proving
expensive failures.
• In the present system, large, vertically integrated pharmaceutical companies retain
in-house expertise at each phase of drug discovery and development. They protect
their property interests through patents on molecules, most of which never become
approved drugs.
• According to pharmaceutical industry data, a new drug can take 10-15 years to
develop and bring to market. For every 5,000-10,000 compounds that enter the
research and development (R&D) pipeline, only one receives approval. Although
substantial variation exists in estimating drug development costs, industry analysts
estimate that companies spend $1 billion to $4 billion in R&D for every new drug
brought to market.
• Increasing public and political pressure to lower prescription drug prices may
signal lower returns on a company’s R&D investment. In response, pharmaceutical
companies have shifted their focus to opportunities that promise only the broadest
markets or the most favorable pricing, such as those for cancer treatment. Companies
have also pursued a strategy of mergers, but there is no evidence to suggest that these
mergers have fostered innovation or accelerated the delivery of new drugs.

Toward a more modular,
disaggregated model of drug
development

Drug development passes through several stages, including: [1] the identification of
drug targets—typically through an understanding of the biological pathways of health
and disease; [2] medicinal chemistry, in which molecules are structured to attack such
targets; [3] “drugability” in which those molecules are modified so that their absorption,
distribution, metabolism, and elimination are consistent with their use in humans;
[4] proof of concept (POC) studies in cells, animal, or human models; and [5] clinical
development, including Phase I-IV trials required by the FDA.
• In the traditional model of drug development, the pharmaceutical company
has expertise in all of these phases, with much more limited roles for academia
and biotechnology companies. As illustrated below, the traditional approach is
slowly shifting to a modular, collaborative one that capitalizes on the strengths of
government, academia, industry, and non-profit organizations. Depending on the
project, expertise can be drawn from any sector, with risk distributed among the
various stakeholders.
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• Examples of this approach exist in the not-for-profit sector, including Medicines for
Malaria Venture (MMV), TB Alliance, and Institute for OneWorld Health. These
product development partnerships (PDPs) have taken on R&D for neglected diseases
where there is little commercial incentive to develop drugs. Although the details
vary, they usually operate as virtual R&D organizations, drawing on the expertise
of a group to identify targets and partnering with a network of research institutions
and companies to outsource activities, using philanthropic resources and in-kind
contributions from partners. One analysis found that PDPs introduced nine new
products for TB, malaria, meningitis, and leishmaniasis in 10 years, compared to
14 new drugs developed for neglected diseases in the previous 25 years.

Re-engineering the process
calls for changes in
educational, regulatory,
and informatics infrastructure

The transition to a more modular approach will require linked initiatives among
academia, the pharmaceutical industry, the National Institutes of Health (NIH),
and the FDA.
• It will have to address the serious deficit in scientists with expertise in translation
medicine and therapeutics (TMAT) and regulatory science. A working group
recently recommended that the NIH develop clear career tracks for translational
medicine, with programs that include training in clinical pharmacology, systems
biology, biomarker development, and cross-sector training with the FDA and the
pharmaceutical industry. The Wellcome Trust has funded four centers of excellence
in Great Britain; each center has an industrial partner that contributes expertise to
the teaching program and an environment where trainees can be exposed to drug
development in the setting of a for-profit company.
• Increasingly, policymakers are recognizing that encouraging and rewarding
innovation requires changes in regulations, and that improving regulations requires
science of its own—regulatory science. Regulatory reforms could protect and
expand the precompetitive space, fostering an earlier, more thorough understanding
of drug action. The FDA might create a “safe haven” for systems physiology and
pharmacology, akin to its approach to pharmacogenomics. The FDA could also
consider incentives for earlier detection of adverse events and unintended therapeutic
effects by using a more graded or gradual approach to introduction to and withdrawal
from the marketplace.
• The new approach requires an informatics infrastructure that permits global, secure,
and compliant sharing of data across academic, industry, and regulatory sectors.
Some of this activity has begun. For example, the NIH Chemical Genomics Center
(NCGC) recently created the NCGC Pharmaceutical Collection, a complete list of
all approved molecular entities as a freely available electronic resource and a physical
collection of small molecules available for further screening for new uses in rare and
neglected diseases.
• Recognizing the need to re-engineer the translational process, the NIH has proposed
a new National Center for Advancing Translational Science, which would aggregate
existing resources pertinent to translational medicine. The proposed center would
house the 60 existing Clinical and Translational Science Awards (CTSAs) and their
educational infrastructure, as well as a collaboration between the NIH and FDA, and
foster academia-industry interactions.

POLICY IMPLICATIONS

The current drug development process is inefficient and unsustainable. Development,
approval, and monitoring of drugs will rely increasingly on coordination and collaboration
among industry, academia, and regulatory bodies, as well as on the sharing of information
in an open and timely manner. Several initiatives at the NIH and FDA are underway to
facilitate the shift to a more modular, collaborative model.
• In August 2011, the FDA released a strategic plan for advancing regulatory science.
The plan calls for the FDA to develop new tools, standards, disease models and sciencebased pathways to improve the speed, efficiency, predictability, capacity and quality of
the entire process, from drug development to evaluation to manufacturing. However,
budget restrictions have eliminated the FDA’s plans to devote an additional $25 million
to regulatory science. The initiative is now being supported through existing funds,
which will likely limit its scope.
• The proposed National Center for Advancing Translational Science (NCATS) has run
into political and budgetary obstacles. As of this writing, it remains unfunded. The
original proposal called for NCATS to be supported through transfer of funds from
existing institutes (primarily the National Center for Research Resources, which would
be eliminated) and the $100 million authorized (though not appropriated) for the
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Cures Acceleration Network, a drug development grant program included in last year’s
health reform legislation. More efforts are needed to communicate how, in this new
drug development model, NCATS will complement, rather than compete with, public
and private sector translational activities.
• The FDA Science Board recently recommended funding FDA Centers of Excellence
within academia. Such centers would provide FDA experts in regulatory science with
a critical mass of complementary expertise and a neutral testing ground on which to
explore drug action independent of the sponsor while remaining mindful of proprietary
interests—a kind of Jet Propulsion Laboratory for the FDA. A call for one such
center—limited to within 50 miles of the FDA campus—has recently been made.
• A key issue in applying the non-profit modular model to the for-profit world of
drug development is the role of intellectual property and patents. A new framework
of intellectual property should be considered—one that rewards successful R&D
investment while encouraging early collaboration and data sharing. Perhaps the
financial rewards of a patent should be postponed until a drug is a profitable success—
and a formal mechanism found to distribute rewards among all those who helped make
it happen.
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